XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.18

-0.4%

12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (6612)	7/2/1998 8:03:00 PM
From: aknahow	Read Replies (1) of 17367

Interesting article on TSC or thestreet.com by Jessie Eisinger on PGNS. Free trial available and an actual subscription is less than $70 per year. A small part of the story is pasted here: Like other doctors, Seilheimer worries that chronic use of high doses of tobramycin via TOBI will cause bacteria to develop resistance to the drug, leaving the antibiotic ineffective. While clinical trials haven't yet revealed resistance problems, "everyone feels you're going to have increased resistance," Seilheimer says. In addition, some doctors say they don't plan to use TOBI to treat chronically ill patients. Instead, they'll only use it on patients who develop complications from their bacterial infections. Dr. David Orenstein, of Children's Hospital in Pittsburgh, estimates that he's treating about 5% to 10% of his patients with TOBI. Of those, he's treating just 30% chronically. The rest get the drug only when they have "acute exacerbations," or serious infections.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next